OM
AIMT

Opaleye Management’s Aimmune Therapeutics AIMT Stock Holding History

Opaleye Management’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-130,000
Closed -$2.71M – 59
2019
Q2 		$2.71M Sell
130,000
-35,000
-21% -$721K 0.83% 34
2019
Q1 		$3.69M Buy
165,000
+15,000
+10% +$353K 1.02% 37
2018
Q4 		$3.59M Buy
+150,000
New +$3.88M 1.34% 24

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Opaleye Management's AIMT Position: Q3 2019 in Review

Opaleye Management sold out of Aimmune Therapeutics (AIMT) in Q3 2019, closing a stake of 130,000 shares — an estimated $2.71M sold.

Opaleye Management first reported a position in AIMT in Q4 2018 and held it in 3 quarters. The position peaked at $3.69M in Q1 2019. 146 funds tracked by Wall St. Rank hold AIMT as of Q3 2019.

  • Opaleye Management reported no remaining Aimmune Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Opaleye Management sold 130,000 Aimmune Therapeutics shares in Q3 2019, an estimated $2.71M.
  • Opaleye Management first reported a position in Aimmune Therapeutics in Q4 2018 and held it in 3 quarters.
  • Opaleye Management's Aimmune Therapeutics position peaked at $3.69M in Q1 2019.
  • 146 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2019.

Based on Opaleye Management's 13F filing for Q3 2019, filed 14 Nov 2019.